Amneal Pharmaceuticals, Inc. Class A Common Stock logo

Amneal Pharmaceuticals, Inc. Class A Common Stock(AMRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
STRONG BUY
BUY for 39 days
PROFIT SINCE LAST BUY
+9.64% ▲
LAST CLOSE
$21.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AMRX

11/13/2026: AMRX (5-star) is a STRONG-BUY. BUY for 39 days. Simulated Profits (9.64%). Updated daily EoD!

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company operating across affordable medicines, specialty pharmaceuticals, and institutional distribution. The company's primary business strengths lie in its vertically integrated manufacturing footprint and successful execution in complex generics and branded neurology treatments like Crexont. Its core growth story centers on scaling high-margin specialty assets and expanding into high-growth global biosimilar markets following strategic platform additions. Key risks include intense generic price competition, regulatory oversight, and debt management obligations. The stock suits growth-oriented healthcare investors willing to monitor pipeline execution and deleveraging progress over the long term.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveAmneal offers solid top-line expansion fueled by complex generics, specialty CNS products, and emerging biosimilar drivers.
Momentum investorMixed fitMomentum fit is conditional on positive technical breakouts and sustained positive earnings revisions.
Value investorModerate fitThe stock provides reasonable valuation multiples relative to major biotech peers, tempered by debt considerations.
Dividend investorWeak fitAmneal does not currently distribute a cash dividend, focusing capital allocation on growth and deleveraging.
Low-risk investorWeak fitPharmaceutical regulatory pressures, execution risks, and debt levels introduce notable equity volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock experiences fluctuations driven by earnings reports, regulatory updates, and broader healthcare sector sentiment.
Valuation riskMediumValuation levels depend heavily on management's ability to meet multi-year operational and EBITDA growth targets.
Competition risk (generic price erosion)HighIntense competition from major generic manufacturers can put downward pressure on product pricing and profit margins.
Business qualityMedium / highAmneal possesses an established global infrastructure and a diversified portfolio across complex generics and specialty brands.
Dividend incomeLow / noneIncome-focused investors will find no dividend yield since earnings are reinvested into the business.
Execution riskMedium / highSuccessful integration of recent acquisitions like Kashiv and pipeline execution are critical to achieving long-term strategic goals.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.45B USD
Price to earnings Ratio 53.45
1Y Target Price 24.29
Price to earnings Ratio 53.45
1Y Target Price 24.29
Volume (30-day avg) 4.0M shares
Beta 1.21
52 Weeks Range 11.39 - 22.07
Updated Date 11/15/2026
52 Weeks Range 11.39 - 22.07
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.4

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 27.96%
Avg. Invested days 39
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AMRX receives a 4-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
AMRX has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+161.6%) and solid cash generation (FCF margin 8.9%) are partially offset by moderate revenue growth (+8.0%), soft profitability (net margin 2.4%).

Financial Health Rating

★★★★★
AMRX's financial health is supported by solid cash strength, including free-cash-flow generation (8.9% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is AMRX's strongest growth driver at +161.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+22.6%, solid) is also solid, while revenue growth (+8.0%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 49.0% and approximately 61.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 52.32% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.62%
TPG GP A, LLC 3.54%
Vanguard Portfolio Management, LLC 3.48%
Rubric Capital Management LP 2.92%
Vanguard Capital Management, LLC 2.21%

Unit Economics (Per $1K Revenue)

★★★★★
AMRX generates approximately $376 of gross profit, $140 of operating income, and $89 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 8.10%

Quantitative Style Profile

★★★★★
AMRX has a high-quality, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Affordable Medicines SegmentRevenues from immediate and extended-release oral solids, powders, liquids, sterile injectables, and complex generics.This is the core volume driver providing stable cash flows through high-volume generic drug distribution.
Specialty SegmentBranded pharmaceutical sales focusing on central nervous system conditions (like Crexont and Rytary) and endocrine care (like Unithroid).This segment delivers higher profit margins and proprietary intellectual property value.
AvKARE SegmentGovernment and institutional label distribution, repackaging, and federal supply channel services.Acts as an institutional distribution channel adding reliable recurring revenue from government agencies.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When Before Market
Estimate 0.23
Actual 0.24

Profitability

Profit Margin 4.17%
Operating Margin (TTM) 16.69%

Management Effectiveness

Return on Assets (TTM) 7.52%
Return on Equity (TTM) 70%

Valuation

Trailing PE 53.45
Forward PE 18.28
Enterprise Value 10.57B
Price to Sales(TTM) 2.33
Enterprise Value 10.57B
Price to Sales(TTM) 2.33
Enterprise Value to Revenue 3.31
Enterprise Value to EBITDA 16.56
Shares Outstanding 348.41M
Shares Floating 215.33M
Shares Outstanding 348.41M
Shares Floating 215.33M
Percent Insiders 52.32
Percent Institutions 48.98

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.